New Disease Treatments
Andhra Pradesh ~ India ~ International ~ City ~ Entertainment ~ Business ~ Sports ~ Technology ~ Health ~ Features
2010 Commonwealth Games ~ 2010 Nobel Prizes ~ Sachin Tendulkar ~ Rajasthan Royals ~ Kings XI Punjab ~ Sushil Kumar ~ Deepika Kumari ~ Somdev Devvarman ~ HR Bhardwaj
Home / India News / 2007 / February / February 2, 2007
New Disease Treatments Emerge as Leaders in the Transdermal Drug Delivery Market

Top News

144 Section in Hyderabad ahead of Ayodhya verdict

Manmohan Singh to campaign in Bihar today

FBI failed to act on Headley's wife's terror link expose 3 yrs before Mumbai attacks

Craven's horror flicks 'were inspired by real stories'

RBI will intervene if inflows turn lumpy: Subbarao

Enforcement Directorate issues 'Look Out Circular' against Lalit Modi

Now, laser technology that destroys tumours using heat

Waist size, not BMI can foretell cardiovascular risk in children

New Disease Treatments Emerge as Leaders in the Transdermal Drug Delivery Market

Mumbai, Maharashtra, India

New opportunities are emerging in the transdermal drug delivery market after the two largest revenue-producing patches suffered major setbacks. The market expects to sustain growth by the newest drugs launched in the central nervous system disorders segment. These new products are expected to expose new patients and physicians to the market, improving the perception and showcase the utility of transdermal patches.

Frost & Sullivan (http://www.pharma.frost.com) finds that U.S. Transdermal Drug Delivery Market earned revenues of $2.97 billion in 2005 and estimates this to reach $4.47 billion in 2012.

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants an overview of the latest analysis of the U.S. Transdermal Drug Delivery Market then send an e-mail to Shwetha Thomas , Corporate Communications, at sthomas@frost.com with the following information: your full name, company name, title, telephone number, e-mail address, city, state, and country. We will send you the information via email upon receipt of the above information.

"New indications previously never treated with patches such as depression, attention deficit hyperactivity disorder, and Parkinson's disease are expanding the market and providing patients with new therapies to manage their diseases", states Frost & Sullivan Industry Analyst Jason McKinnie.

Disorders of the central nervous system are providing substantial opportunity for the transdermal market. Previously CNS diseases were treated with oral or injection-based therapies, but transdermal offers advantages such as dosing control that are unavailable with other delivery methods. With patent expiration of Duragesic and recent trouble with Ortho Evra, the CNS market is expected to sustain growth of the total transdermal segment until new products in other segments enter the market in 2009.

The transdermal drug delivery market is still suffering from a patent expiration and a label change that occurred in 2005. Duragesic was the largest revenue-generating patch in the market with over $1.2 billion in its last full year of patent protection. Ortho Evra underwent a label change in November 2005 that warned patients were exposed to 60% more estrogen in the patch versus the oral formulation. The then second largest product suffered dramatic revenue declines as a result. In the period of one year, the two largest revenue-generating patches dropped dramatically affecting the total transdermal market.

"In 2005, the transdermal drug delivery market suffered major setbacks to the two most revenue-generating patches. The patent expiration and label change led to a dramatic decrease in revenues for 2005 and eliminated expectations of total market growth in 2006", notes McKinnie.

Companies have an opportunity to capitalize on these setbacks by offering competitive products that utilize superior technology or enhanced safety. Patients and physicians have proven they trust transdermal technologies for pain management and birth control, and these recent setbacks offer an opportunity for new companies to enter the market space without these established competitors.

U.S. Transdermal Drug Delivery Market is part of the pharmaceutical subscription, which also includes research in the following markets: U.S. Intranasal Drug Delivery, Analysis of Top 10 Specialty Pharmaceutical Companies, and Global Pharmaceutical Contract Manufacturing Markets. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews are available to the press.

Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit http://www.frost.com.

U.S. Transdermal Drug Delivery Market
F791-52

Shwetha Thomas, Corporate Communications - South Asia & Middle East, Frost & Sullivan, +91 (022) 4001 3429 sthomas@frost.com

Melina Trevino, Corporate Communications - North America, Frost & Sullivan, +210 247 2440 melina.trevino@frost.com

Source: Frost & Sullivan (Business Wire India)

Press release presented here is sourced from the Source mentioned above and is provided on as-is basis. Please contact the Company / Source directly for any further information in regard to this release. This website will be unable to assist you in regard to the accuracy or correctness of information in this release.

India News / Press Releases on February 2, 2007

Delhi Hosts the First 'Mobile Security India 2007' Seminar
Business Wire India

Fuelled by Local Competitors, the European in-the-Cloud Managed Security Services Market Takes off
Business Wire India

New Disease Treatments Emerge as Leaders in the Transdermal Drug Delivery Market
Business Wire India

Also see International News / Press Releases on February 2, 2007

Suggested pages for your additional reading
AndhraNews.net on Facebook






© 2000-2017 AndhraNews.net. All Rights Reserved and are of their respective owners.
Disclaimer, Terms of Service & Privacy Policy | Contact Us